Oncology specialist Volastra brings in PhI drug from Amgen, nabs $60M in Series A

Paul Schloesser

Associate Editor

Almost a year after inking a billion-dollar biobucks deal with Bristol Myers Squibb, NYC biotech Volastra Therapeutics is linking up with two other pharma giants …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER

Oncology specialist Volastra brings in PhI drug from Amgen, nabs $60M in Series A

Paul Schloesser

Associate Editor

Sign up to read this article for free.

Global Head of Marketing

Bachem

Bubendorf, BL, Switzerland

Bluebird bio to sell to investment funds after struggling to make money from gene therapies

CBER's deputy director departs as staff shakeup continues

Eli Lilly stockpiles $548M of oral weight loss drug ahead of launch

Will CRISPR matter?

FDA approves first drug to treat ultra-rare lipid storage disease

Trusted protection: Why the current meningococcal vaccination schedule shouldn’t change without strong evidence

On­col­o­gy spe­cial­ist Volas­tra brings in PhI drug from Am­gen, nabs $60M in Se­ries A

Associate Editor

Sign up to read this article for free.

Bachem

Bubendorf, BL, Switzerland

Oncology specialist Volastra brings in PhI drug from Amgen, nabs $60M in Series A